We used MT12 monotherapy, MT12 combined with the ROS blocker NAC, and MT12 combined with JNK inhibitors (SP600125) to treat BC cells to see whether it affects autophagy by increasing intracellular ROS and then activating the JNK/P53 signaling pathway. This evidence concerns the gene TP53 and breast cancer.